Detailed description page of ThPDB2
| This page displays user query in tabular form. |
Th1053 details |
| Primary information | |
|---|---|
| ID | 10365 |
| Therapeutic ID | Th1053 |
| Protein Name | Serum albumin iodonated |
| Sequence | >Th1053_Serum_albumin_iodonated MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL |
| Molecular Weight | 66472.2 |
| Chemical Formula | C2936H4624N786O889S41 |
| Isoelectric Point | 5.67 |
| Hydrophobicity | -0.395 |
| Melting point | 62 |
| Half-life | NA |
| Description | A diagnostic radiopharmaceutical containing iodinated I 131 albumin for intravenous imaging. Following Intravenous infusion, radioiodinated albumin human is uniformly distributed throughout the intravascular pool within 10 minutes; extravascular distribution takes place more slowly (2 days). Indicated for use in determinations of total blood and plasma volumes, cardiac output, cardiac and pulmonary blood volumes and circulation times |
| Indication/Disease | For determination of total blood and plasma volumes |
| Pharmacodynamics | Regulates the colloidal osmotic pressure of blood. It is used to increase the circulating plasma volume, thereby reducing hemoconcentrtion and blood viscosity. Also used as a transport protein that binds naturally occurring, therapeutic and toxic materials in circulation. |
| Mechanism of Action | Serum albumin acts as a high molecular weight, very soluble osmolyte. |
| Toxicity | In general, human albumin solutions are well-tolerated and no specific, clinically relevant alterations in organ function or coagulopathy have been substantiated. The most common adverse reactions are rigors, hypotension, tachycardia with increased heart rate, fever, chills, nausea, vomiting, dyspnea and/or bronchospasm, skin rash/pruritus. Stop the infusion immediately if anaphylaxis, with or without shock is observed. Hypervolemia may occur if the dosage and rate of infusion are not adjusted to the volume status of the patient. When clinical signs of cardiovascular overload occur (headache, dyspnea, jugular venous distention, increased blood pressure), the infusion must be slowed or stopped immediately. |
| Metabolism | NA |
| Absorption | NA |
| Albumin is distributed throughout the extracellular space and more than 60% of the body albumin pool is located in the extravascular fluid space . In healthy adults, less than 10% of infused albumin leaves the intravascular compartment during the first 2 hours following infusion of albumin. There is considerable individual variation in the effect of albumin on plasma volume, however. In some patients, the plasma volume can remain elevated for several hours. In critically ill patients, however, albumin can leak out of the vascular space in substantial amounts at an unpredictable rate that is difficult to predict. | |
| Clearance | NA |
| Categories | Albumins, Amino Acids, Peptides, and Proteins, Blood and Blood Forming Organs, Blood and Related Products, Blood Derivatives, Blood Proteins, Blood Substitutes and Perfusion Solutions, Blood Substitutes and Plasma Protein Fractions, Cardiac Function, Diluents, Human Serum Albumin, Increased Intravascular Volume, Increased Oncotic Pressure, Osmotic Activity, Proteins, Serum Albumin |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Apolipoprotein E,Serum amyloid A-1 protein,Protein AMBP, Nitric oxide |
| Brand Name | Megatope |
| Company | IsoTex Diagnostics |
| Brand Description | IsoTex Diagnostics |
| Prescribed For | Megatope (Iodinated I 131 Albumin Injection) is indicated for use in determinations of total blood and plasma volumes, cardiac output, cardiac and pulmonary blood volumes and circulation times, and in protein turnover studies, heart and great vessel,dilineation, localization of the placenta, and localization of celebral neospasms |
| Chemical Name | NA |
| Formulation | Each mL of sterile, nonpyrogenic, aqueous, colorless to very pale yellow solution provides approximate 10 mg, protein (albumin human), 16 mg dibasic sodium phosphate, 1.6 mg monobasic, sodium phosphate, not more than 0.4 guanidine hydrochloride, sodium chloride, for isotonicity, and 9 mg benzyl alcohol as a preservative. |
| Physical Appearance | Megatope (Iodinated I 131 Albumin Injection) may be colorless to very pale yellow solution |
| Route of Administration | Injection for Intravenous administration |
| Recommended Dosage | The total dosage administered in any one week should not exceed 200 microcuries |
| Contraindication | None Known. |
| Side Effects | Although the immunological properties of albumin human are believed to be virtually unaltered by the iodination process, there is a theoretical possibility that allergic reactions may occur in patients receiving additional doses a number of weeks after an initial dose. |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 10366 |
| Therapeutic ID | Th1053 |
| Protein Name | Serum albumin iodonated |
| Sequence | >Th1053_Serum_albumin_iodonated MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL |
| Molecular Weight | 66472.2 |
| Chemical Formula | C2936H4624N786O889S41 |
| Isoelectric Point | 5.67 |
| Hydrophobicity | -0.395 |
| Melting point | 62 |
| Half-life | NA |
| Description | A diagnostic radiopharmaceutical containing iodinated I 131 albumin for intravenous imaging. Following Intravenous infusion, radioiodinated albumin human is uniformly distributed throughout the intravascular pool within 10 minutes; extravascular distribution takes place more slowly (2 days). Indicated for use in determinations of total blood and plasma volumes, cardiac output, cardiac and pulmonary blood volumes and circulation times |
| Indication/Disease | For determination of total blood and plasma volumes |
| Pharmacodynamics | Regulates the colloidal osmotic pressure of blood. It is used to increase the circulating plasma volume, thereby reducing hemoconcentrtion and blood viscosity. Also used as a transport protein that binds naturally occurring, therapeutic and toxic materials in circulation. |
| Mechanism of Action | Serum albumin acts as a high molecular weight, very soluble osmolyte |
| Toxicity | In general, human albumin solutions are well-tolerated and no specific, clinically relevant alterations in organ function or coagulopathy have been substantiated. The most common adverse reactions are rigors, hypotension, tachycardia with increased heart rate, fever, chills, nausea, vomiting, dyspnea and/or bronchospasm, skin rash/pruritus. Stop the infusion immediately if anaphylaxis, with or without shock is observed. Hypervolemia may occur if the dosage and rate of infusion are not adjusted to the volume status of the patient. When clinical signs of cardiovascular overload occur (headache, dyspnea, jugular venous distention, increased blood pressure), the infusion must be slowed or stopped immediately. |
| Metabolism | NA |
| Absorption | NA |
| Albumin is distributed throughout the extracellular space and more than 60% of the body albumin pool is located in the extravascular fluid space . In healthy adults, less than 10% of infused albumin leaves the intravascular compartment during the first 2 hours following infusion of albumin. There is considerable individual variation in the effect of albumin on plasma volume, however. In some patients, the plasma volume can remain elevated for several hours. In critically ill patients, however, albumin can leak out of the vascular space in substantial amounts at an unpredictable rate that is difficult to predict. | |
| Clearance | NA |
| Categories | Albumins, Amino Acids, Peptides, and Proteins, Blood and Blood Forming Organs, Blood and Related Products, Blood Derivatives, Blood Proteins, Blood Substitutes and Perfusion Solutions, Blood Substitutes and Plasma Protein Fractions, Cardiac Function, Diluents, Human Serum Albumin, Increased Intravascular Volume, Increased Oncotic Pressure, Osmotic Activity, Proteins, Serum Albumin |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Rilonacept results in increased immunosuppressive effects; increases the risk of infection |
| Target | NA |
| Brand Name | Jeanotope |
| Company | IsoTex Diagnostics |
| Brand Description | IsoTex Diagnostics |
| Prescribed For | Jeanotope I-125 is indicated for use in the determination of total blood and plasma volume. |
| Chemical Name | NA |
| Formulation | Each milliliter provides approximately 10 mg protein (normal human serum albumin), 1.6 mg sodium phosphate, 16 mg sodium biphosphate, not more than 0.4 mg guanidine hydrochloride, sodium chloride for isotonicity, and 9 mg benzyl alcohol as a preservative. The stabilizer aceryltryptophanate and sodium caprylate have a concentration of less, than 0.0089M. |
| Physical Appearance | Jeanatope 1-125 (Iodinated 1-125 Albumin Injection) is a Sterile, nonpyrogenic, aqueos solution |
| Route of Administration | Intravenous infusion |
| Recommended Dosage | When a procedure such as a blood volume determination is to be repeated, the total dosage administered in any one week should not exceed 7.4 megabecquerels, (200 microcuries). |
| Contraindication | At present there are no known contraindications to the use of this preparation |
| Side Effects | Although the immunological properties of albumin human are believed to be virtually unaltered by the iodination process, there is a theoretical possibility that allergic reactions may occur in patients receiving additional doses a number of weeks after an initial dose. |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 10367 |
| Therapeutic ID | Th1053 |
| Protein Name | Serum albumin iodonated |
| Sequence | >Th1053_Serum_albumin_iodonated MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL |
| Molecular Weight | 66472.2 |
| Chemical Formula | C2936H4624N786O889S41 |
| Isoelectric Point | 5.67 |
| Hydrophobicity | -0.395 |
| Melting point | 62 |
| Half-life | NA |
| Description | A diagnostic radiopharmaceutical containing iodinated I 131 albumin for intravenous imaging. Following Intravenous infusion, radioiodinated albumin human is uniformly distributed throughout the intravascular pool within 10 minutes; extravascular distribution takes place more slowly (2 days). Indicated for use in determinations of total blood and plasma volumes, cardiac output, cardiac and pulmonary blood volumes and circulation times |
| Indication/Disease | For determination of total blood and plasma volumes |
| Pharmacodynamics | Regulates the colloidal osmotic pressure of blood. It is used to increase the circulating plasma volume, thereby reducing hemoconcentrtion and blood viscosity. Also used as a transport protein that binds naturally occurring, therapeutic and toxic materials in circulation. |
| Mechanism of Action | Serum albumin acts as a high molecular weight, very soluble osmolyte |
| Toxicity | In general, human albumin solutions are well-tolerated and no specific, clinically relevant alterations in organ function or coagulopathy have been substantiated. The most common adverse reactions are rigors, hypotension, tachycardia with increased heart rate, fever, chills, nausea, vomiting, dyspnea and/or bronchospasm, skin rash/pruritus. Stop the infusion immediately if anaphylaxis, with or without shock is observed. Hypervolemia may occur if the dosage and rate of infusion are not adjusted to the volume status of the patient. When clinical signs of cardiovascular overload occur (headache, dyspnea, jugular venous distention, increased blood pressure), the infusion must be slowed or stopped immediately. |
| Metabolism | NA |
| Absorption | NA |
| Albumin is distributed throughout the extracellular space and more than 60% of the body albumin pool is located in the extravascular fluid space . In healthy adults, less than 10% of infused albumin leaves the intravascular compartment during the first 2 hours following infusion of albumin. There is considerable individual variation in the effect of albumin on plasma volume, however. In some patients, the plasma volume can remain elevated for several hours. In critically ill patients, however, albumin can leak out of the vascular space in substantial amounts at an unpredictable rate that is difficult to predict. | |
| Clearance | NA |
| Categories | Albumins, Amino Acids, Peptides, and Proteins, Blood and Blood Forming Organs, Blood and Related Products, Blood Derivatives, Blood Proteins, Blood Substitutes and Perfusion Solutions, Blood Substitutes and Plasma Protein Fractions, Cardiac Function, Diluents, Human Serum Albumin, Increased Intravascular Volume, Increased Oncotic Pressure, Osmotic Activity, Proteins, Serum Albumin |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Brand Name | Volumex |
| Company | IsoTex Diagnostics |
| Brand Description | IsoTex Diagnostics |
| Prescribed For | Volumex (Iodinated I 131 Allbumin injection) is indicated for use in determination of total blood and plasma volumes and in protein turnover studies |
| Chemical Name | NA |
| Formulation | Each ml of nonpyrogenic, aqueous, colorless to very pale yellow solution provides approximately 10 mg protein (albumin human), 16 mg dibasic sodium phosphate, 1.6 mg monobasic sodium phosphate, not more, than 0.4 mg guanidine hydrochloride, sodium chloride for isotonicity, and 9 mg benzyl alcohol as a preservative. |
| Physical Appearance | Volumex (Iodinated I 131 Albumin Injection) may be colorless to very pale yellow solution. |
| Route of Administration | Intravenous infusion |
| Recommended Dosage | When a procedure such as a blood volume determination is to be repeated, the total dosage administered in any one week should not exceed 200 microcuries |
| Contraindication | None Known. |
| Side Effects | Although the immunological properties of albumin human are believed to be virtually unaltered by the iodination process, there is a theoretical possibility that allergic reactions may occur in patients receiving additional doses a number of weeks after an initial dose. |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |